J. Buchbjerg

Vortioxetine reduces BOLD signal during performance of the N-back working memory task: a randomised neuroimaging trial in remitted depressed patients and healthy controls

G. Dawson, J. Deakin, C. Harmer, 2017, Molecular Psychiatry.

A multinational , randomized , double-blind , placebo-controlled Phase 2 study to assess safety and efficacy of olesoxime ( TRO 19622 / RG 6083 ) in patients with Type 2 or non-ambulatory Type 3 spinal muscular atrophy

G. Comi, E. Mercuri, P. Fontoura, 2019 .

Pharmacodynamic interaction between intravenous nitroglycerin and oral sacubitril/valsartan (LCZ696) in healthy subjects

J. Buchbjerg, G. Golor, P. Pal, 2018, European Journal of Clinical Pharmacology.

Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial

E. Mercuri, F. Muntoni, F. Rivier, 2017, The Lancet Neurology.

Pharmacokinetic Drug Interactions Involving Vortioxetine (Lu AA21004), a Multimodal Antidepressant

J. Buchbjerg, R. Lee, Grace Chen, 2013, Clinical Drug Investigation.

Tisotumab vedotin in Japanese patients with recurrent/metastatic cervical cancer: Results from the innovaTV 206 study

K. Yonemori, J. Buchbjerg, Y. Hirashima, 2022, Cancer science.

P.1.g.013 Effects of vortioxetine versus paroxetine on polysomnography in man: a pharmacokinetic/pharmacodynamic study

D. Nutt, S. Wilson, J. Buchbjerg, 2013, European Neuropsychopharmacology.